CytoPathfinder, a Japanese startup developing microarrays and drug-delivery technologies, last week said that Qiagen will supply it siRNAs for use on its transfection microarray for high-throughput RNAi screening.

CytoPathfinder said the deal not only gives it access to Qiagen's HiPerformance siRNA design algorithm, which it licensed from Novartis in late 2003 (see RNAi News, 12/19/2003), but a partner with a global reach — something that could prove vital for the Japanese startup as it eyes overseas markets.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.

A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.

Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.

In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.